Surgical Science Q3 2024: Slight top-line beat, margins roughly in line - Redeye

Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations. We judge that notable positives from the report include sales, especially Educational Products, beating our estimates, while margins roughly aligned with our projections. Notable negatives include soft cash flow and Surgical Science noting that Educational Products is unlikely to post y/y growth for FY 2024e. Overall, we judge Surgical Science delivered a solid Q3, and the share will likely react positively to its third-quarter figures.

Länk till analysen i sin helhet: https://www.redeye.se/research/1056536/surgical-science-q3-2024-slight-top-line-beat-margins-roughly-in-line?utm_source=finwire&utm_medium=RSS